These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 28823711

  • 1. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.
    Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, Thakur GA, Hohmann AG.
    Biol Psychiatry; 2018 Nov 15; 84(10):722-733. PubMed ID: 28823711
    [Abstract] [Full Text] [Related]

  • 2. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
    Slivicki RA, Xu Z, Mali SS, Hohmann AG.
    Pharmacol Res; 2019 Apr 15; 142():267-282. PubMed ID: 30739035
    [Abstract] [Full Text] [Related]

  • 3. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
    Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG.
    Biol Psychiatry; 2015 Mar 01; 77(5):475-87. PubMed ID: 24853387
    [Abstract] [Full Text] [Related]

  • 4. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
    Slivicki RA, Saberi SA, Iyer V, Vemuri VK, Makriyannis A, Hohmann AG.
    J Pharmacol Exp Ther; 2018 Dec 01; 367(3):551-563. PubMed ID: 30275151
    [Abstract] [Full Text] [Related]

  • 5. Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward.
    Slivicki RA, Iyer V, Mali SS, Garai S, Thakur GA, Crystal JD, Hohmann AG.
    Front Mol Neurosci; 2020 Dec 01; 13():54. PubMed ID: 32410959
    [Abstract] [Full Text] [Related]

  • 6. CB1 positive allosteric modulation attenuates Δ9-THC withdrawal and NSAID-induced gastric inflammation.
    Trexler KR, Eckard ML, Kinsey SG.
    Pharmacol Biochem Behav; 2019 Feb 01; 177():27-33. PubMed ID: 30597181
    [Abstract] [Full Text] [Related]

  • 7. Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice.
    Li AL, Carey LM, Mackie K, Hohmann AG.
    J Pharmacol Exp Ther; 2017 Aug 01; 362(2):296-305. PubMed ID: 28592614
    [Abstract] [Full Text] [Related]

  • 8. Peripheral deficiency and antiallodynic effects of 2-arachidonoyl glycerol in a mouse model of paclitaxel-induced neuropathic pain.
    Thomas A, Okine BN, Finn DP, Masocha W.
    Biomed Pharmacother; 2020 Sep 01; 129():110456. PubMed ID: 32603895
    [Abstract] [Full Text] [Related]

  • 9. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
    Deng L, Cornett BL, Mackie K, Hohmann AG.
    Mol Pharmacol; 2015 Jul 01; 88(1):64-74. PubMed ID: 25904556
    [Abstract] [Full Text] [Related]

  • 10. The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence.
    Iyer V, Slivicki RA, Thomaz AC, Crystal JD, Mackie K, Hohmann AG.
    Eur J Pharmacol; 2020 Nov 05; 886():173544. PubMed ID: 32896549
    [Abstract] [Full Text] [Related]

  • 11. Monoacylglycerol Lipase Inhibitors Reverse Paclitaxel-Induced Nociceptive Behavior and Proinflammatory Markers in a Mouse Model of Chemotherapy-Induced Neuropathy.
    Curry ZA, Wilkerson JL, Bagdas D, Kyte SL, Patel N, Donvito G, Mustafa MA, Poklis JL, Niphakis MJ, Hsu KL, Cravatt BF, Gewirtz DA, Damaj MI, Lichtman AH.
    J Pharmacol Exp Ther; 2018 Jul 05; 366(1):169-183. PubMed ID: 29540562
    [Abstract] [Full Text] [Related]

  • 12. Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.
    Datta U, Kelley LK, Middleton JW, Gilpin NW.
    Psychopharmacology (Berl); 2020 Dec 05; 237(12):3729-3739. PubMed ID: 32857187
    [Abstract] [Full Text] [Related]

  • 13. Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal.
    Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, Hohmann AG.
    Mol Pharmacol; 2019 Feb 05; 95(2):155-168. PubMed ID: 30504240
    [Abstract] [Full Text] [Related]

  • 14. Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice.
    Ghosh S, Kinsey SG, Liu QS, Hruba L, McMahon LR, Grim TW, Merritt CR, Wise LE, Abdullah RA, Selley DE, Sim-Selley LJ, Cravatt BF, Lichtman AH.
    J Pharmacol Exp Ther; 2015 Aug 05; 354(2):111-20. PubMed ID: 25998048
    [Abstract] [Full Text] [Related]

  • 15. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model.
    Adamson Barnes NS, Mitchell VA, Kazantzis NP, Vaughan CW.
    Br J Pharmacol; 2016 Jan 05; 173(1):77-87. PubMed ID: 26398331
    [Abstract] [Full Text] [Related]

  • 16. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.
    Kinsey SG, Wise LE, Ramesh D, Abdullah R, Selley DE, Cravatt BF, Lichtman AH.
    J Pharmacol Exp Ther; 2013 Jun 05; 345(3):492-501. PubMed ID: 23412396
    [Abstract] [Full Text] [Related]

  • 17. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
    Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM, Sinal CJ, Kulkarni PM, Thakur GA, Denovan-Wright EM.
    Neuropharmacology; 2019 Jun 05; 151():1-12. PubMed ID: 30940536
    [Abstract] [Full Text] [Related]

  • 18. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor.
    Khajehali E, Malone DT, Glass M, Sexton PM, Christopoulos A, Leach K.
    Mol Pharmacol; 2015 Aug 05; 88(2):368-79. PubMed ID: 26044547
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure.
    Garai S, Schaffer PC, Laprairie RB, Janero DR, Pertwee RG, Straiker A, Thakur GA.
    Bioorg Med Chem; 2021 Nov 15; 50():116421. PubMed ID: 34634617
    [Abstract] [Full Text] [Related]

  • 20. Increased Contextual Fear Conditioning in iNOS Knockout Mice: Additional Evidence for the Involvement of Nitric Oxide in Stress-Related Disorders and Contribution of the Endocannabinoid System.
    Lisboa SF, Gomes FV, Silva AL, Uliana DL, Camargo LH, Guimarães FS, Cunha FQ, Joca SR, Resstel LB.
    Int J Neuropsychopharmacol; 2015 Jan 24; 18(8):. PubMed ID: 25618404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.